来源：oncologystat
分享：阳光明媚
乳腺癌
GeneExpression Profile 基因表达
1.Paik S, T Gong, Shak S, et al. Gene Expression and Benefit of Chemotherapy inWomen With Node-Negative, Estrogen Receptor–Positive Breast Cancer. J Clin Oncol. August 10, 2006;24(23):3726-3734.
2.Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the21-gene recurrence score assay in postmenopausal women with node-positive,oestrogen-receptor-positive breast cancer on chemotherapy: a retrospectiveanalysis of a randomised trial. Lancet Oncol. January 2010;11(1):55-65.
Prevention/DCIS 预防/导管原位癌
3.Wapnir IL, Dignam JJ, Fisher B, et al. Long-Term Outcomes of InvasiveIpsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24Randomized Clinical Trials for DCIS. J Natl Cancer Inst. Published on-lineMarch 11, 2011.
4.Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for Breast-CancerPrevention in Postmenopausal Women. N Engl J Med. June 23, 2011;364(25):2381-2391.
LocalTherapy 局部治疗
5.Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus Tamoxifen with orwithout Irradiation in Women 70 Years of Age or Older with Early Breast Cancer. N Engl J Med. September 2, 2004;351:971-977.
6.Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillarydissection in women with invasive breast cancer and sentinel node metastasis: arandomized clinical trial. JAMA. 2011; 305(6):569-575.
LocallyAdvanced Breast Cancer/Neoadjuvant Chemotherapy
局部晚期乳腺癌/新辅助化疗
7.Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy onlocal-regional disease in women with operable breast cancer: Findings fromNational Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. July 1, 1997;15(7):2483-2493.
8.Bear HD, Anderson S, Brown A, et al. The effect on tumor response of addingsequential preoperative docetaxel to preoperative doxorubicin andcyclophosphamide: Preliminary results from national surgical adjuvant breastand bowel project protocol B-27. J Clin Oncol. November, 2003; 21(22):4165-4174.
Chemotherapy:Adjuvant 辅助化疗
9.Bonadonna G, Valaqussa P, Moliterni A, et al. Adjuvant Cyclophosphamide,Methotrexate and Fluorouracil in node positive breast cancer: The Results of 20Years of Follow-up. N Engl J Med. April 6, 1995;332(14):901-906.
10.Citron ML, Berry DA, Cirrincione C, et al. Randomized Trial of Dose-DenseVersus Conventionally Scheduled and Sequential Versus Concurrent CombinationChemotherapy as Postoperative Adjuvant Treatment of Node-Positive PrimaryBreast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia GroupB Trial 9741. J Clin Oncol. April 15, 2003;21(8):1431-1439.
11.Henderson IC, Berry DA, Demetri GD, et al. Improved Outcomes From AddingSequential Paclitaxel but Not From Escalating Doxorubicin Dose in an AdjuvantChemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer. J Clin Oncol. March 15, 2003;21(6):976-83.
12.Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects ofchemotherapy and hormonal therapy for early breast cancer on recurrence and15-year survival: an overview of the randomized trials. Lancet. May 14, 2005;365(9472):1687-1717.
13.Jones SE, Savin MA, Holmes FA, et al. Phase III Trial Comparing DoxorubicinPlus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapyfor Operable Breast Cancer. J Clin Oncol. December 1, 2006;24(34)5381-5387.
14.Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvanttreatment of breast cancer. N Engl J Med. April 17, 2008;358(16):1663-1671.
15.Muss HB, Berry DA, Cirrincione C, et al. Adjuvant chemotherapy in older womenwith early-stage breast cancer. N Engl J Med. May 14, 2009;360(20):2055-2065.
HER2-PositiveDisease: Adjuvant HER2+乳腺癌辅助治疗
16.Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapyfor operable HER2-positive breast cancer. N Engl J Med. October 20, 2005;353(16):1673-1684.
17.Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab afteradjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. October 20, 2005;353(16):1659-1672.
HormoneTherapy: Adjuvant 激素辅助治疗
18.Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination withtamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal womenwith early breast cancer: first results of the ATAC randomised trial. Lancet. July 22, 2002;59(9324):2131-2139.
19.Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane aftertwo to three years of tamoxifen therapy in postmenopausal women with primarybreast cancer. N Engl J Med. March 11, 2004;50(11):1081-1092.
20.Breast International Group (BIG) I-98 Collaborative Group: Thurlimann B,Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen inpostmenopausal women with early breast cancer. N Engl J Med. December 29, 2005;353(26):2747-2757.
21.Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole followingtamoxifen as extended adjuvant therapy in receptor-positive breast cancer:updated findings from NCIC CTG MA.17. J Natl Cancer Inst. September 7,2005; 97(17):1262-1271.
22.Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Davies C, GodwinJ, Gray R, et al. (EBCTCG). Relevance of breast cancer hormone receptors andother factors to the efficacy of adjuvant tamoxifen: patient-levelmeta-analysis of randomised trials. Lancet. August 27, 2011;378(9793):771-784.
Chemotherapy:Metastatic Disease 转移性乳腺癌化疗
23.O’Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabineplus docetaxel combination therapy in anthracycline-pretreated patients withadvanced breast cancer: phase III trial results. J Clin Oncol. June 15, 2002;20(12):2812-2823.
24.Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin,paclitaxel, and the combination of doxorubicin and paclitaxel as front-linechemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. February 15, 2003;21(4):588-592.
25.Gradishar WJ, Tjulandin S , Davidson N , et al. Phase III trial of nanoparticlealbumin-bound paclitaxel compared with polyethylated castor oil basedpaclitaxel in women with breast cancer. J Clin Oncol. November 1, 2005;23(31):7794-7803.
26.Cortes J, O’Shaughnessy J, Loesch D, et al. Eribulin monotherapy versustreatment of physician's choice in patients with metastatic breast cancer(EMBRACE): a phase 3 open-label randomised study. Lancet. March 12, 2011;377(9769):914-923.
27.Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weeklycompared with every-3-weeks paclitaxel for metastatic breast cancer, withtrastuzumab for all HER-2 overexpressors and random assignment to trastuzumabor not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group Bprotocol 9840. J Clin Oncol. April 1, 2008;26(10):1642-1649.
28.Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus Paclitaxel versusPaclitaxel monotherapy in patients with metastatic breast cancer and prioranthracycline treatment. J Clin Oncol. August 20, 2008;26(24):3950-3957.
HormoneTherapy: Metastatic Disease 转移性乳腺癌激素治疗
29.Chia S, Gradishar WJ, Mauriac L, et al. Double-blind, randomized placebocontrolled trial of fulvestrant compared with exemestane after priornonsteroidal aromatase inhibitor therapy in postmenopausal women with hormonereceptor-positive, advanced breast cancer: results from EFECT. J ClinOncol. April 1, 2008; 26(10):1664-1670.
HER2-PositiveDisease: Metastatic Disease HER2-转移性乳腺癌
30.Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus amonoclonal antibody against HER2 for metastatic breast cancer thatoverexpresses HER2. NEngl J Med. March 15, 2001; 344(11):783-792.
31.Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine forHER2-positive advanced breast cancer. NEngl J Med. December 28, 2006; 355(26):2733-2743.
32.Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinibalone or in combination with trastuzumab in women with ErbB2-positive,trastuzumab-refractory metastatic breast cancer. JClin Oncol. March 1, 2010; 28(7):1124-1130.
HER2-Negative:Bevacizumab: Metastatic Disease 贝伐单抗治疗HER2-转移性乳腺癌
33.Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versuspaclitaxel alone for metastatic breast cancer.NEngl J Med. December 27, 2007; 357(26):2666-2676.
34.Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plusdocetaxel compared with placebo plus docetaxel for the first-line treatment ofhuman epidermal growth factor receptor 2-negative metastatic breast cancer. JClin Oncol. July 10, 2010; 28(20):3239-3247.
责任编辑：Lilith
苏公网安备32059002004080号
